RIL
FDMT icon

Rothschild Investment LLC’s 4D Molecular Therapeutics FDMT Stock Holding History

Rothschild Investment LLC’s Portfolio FDMT Stock Details FDMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$56 Buy
+6
New +$52 ﹤0.01% 3452
2024
Q4 		– Sell
-35
Closed -$378 – 2996
2024
Q3 		$378 Buy
+35
New +$581 ﹤0.01% 2551
2024
Q2 		– Sell
-5
Closed -$159 – 2822
2024
Q1 		$159 Buy
+5
New +$128 ﹤0.01% 1867

Other funds holding FDMT

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Rothschild Investment LLC's FDMT Position: Q1 2026 in Review

Rothschild Investment LLC opened a new position in 4D Molecular Therapeutics (FDMT) in Q1 2026: 6 shares worth $56. The stake represents ﹤0.01% of the portfolio and ranks #3452 among its holdings. This is a return to the name: Rothschild Investment LLC previously reported a position in FDMT as recently as Q3 2024.

Rothschild Investment LLC first reported a position in FDMT in Q1 2024 and has held it in 3 quarters since. The position peaked at $378 in Q3 2024. 152 funds tracked by Wall St. Rank hold FDMT as of Q1 2026.

  • Rothschild Investment LLC held 6 shares of 4D Molecular Therapeutics worth $56 as of Q1 2026.
  • 4D Molecular Therapeutics was a new Rothschild Investment LLC position in Q1 2026.
  • 4D Molecular Therapeutics made up ﹤0.01% of Rothschild Investment LLC's portfolio in Q1 2026, its #3452 holding.
  • Rothschild Investment LLC first reported a position in 4D Molecular Therapeutics in Q1 2024 and has held it in 3 quarters since.
  • Rothschild Investment LLC's 4D Molecular Therapeutics position peaked at $378 in Q3 2024.
  • 152 funds tracked by Wall St. Rank held 4D Molecular Therapeutics as of Q1 2026.

Based on Rothschild Investment LLC's 13F filing for Q1 2026, filed 7 May 2026.